Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | CASR | P41180 | 2/20 | 0.35 |
| ▸ | ESRRB | O95718 | 1/20 | 0.35 |
| ▸ | ESRRG | P62508 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4588833 | 0.85 | PPARG (0.44) | HTR2CCCR2SOS1HTR7PPARG | |
| SCHEMBL4589034 | 0.83 | PPARG (0.44) | HTR2CCCR2SOS1HTR7PPARG | |
| SCHEMBL9618625 | 0.82 | PPARG (0.45) | HTR2CCCR2HTR7PPARGPPARA | |
| SCHEMBL10973444 | 0.82 | PPARG (0.45) | HTR2CCCR2SOS1HTR7PPARG | |
| Hydrochloric Acid SCHEMBL10935760 | 0.82 | PPARG (0.44) | HTR2CCCR2SOS1HTR7PPARG | |
| Hydrochloric Acid SCHEMBL9423232 | 0.82 | PPARG (0.44) | HTR2CCCR2HTR7PPARGPPARA | |
| SCHEMBL9423081 | 0.82 | CCR2 (0.48) | HTR2CCCR2SOS1HTR7PPARG | |
| SCHEMBL9370507 | 0.78 | PPARG (0.45) | HTR2CHTR7PPARGPPARAMEN1 | |
| Hydrochloric Acid SCHEMBL8742191 | 0.78 | PPARG (0.44) | HTR2CHTR7PPARGPPARAMEN1 | |
| SCHEMBL8507316 | 0.77 | CCR2 (0.39) | HTR2CCCR2SOS1HTR7PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381733-B2 | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases | NEUROSEARCH A/S (DK) | 2008-06-03 | — | — | US | disclosed |
| US-7297799-B2 | Preparation of benzoylalkyl-1,2,3,6-tetrahydropyridines and use thereof | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | disclosed |
| US-20070054931-A1 | PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF | SANOFI-AVENTIS (FR) | 2007-03-08 | — | — | US | disclosed |
| US-7160899-B2 | Adenosine A2A receptor antangonists combined with neurotrophic activity compounds in the treatment of Parkinson's disease | NEUROSEARCH A/S (DK) | 2007-01-09 | — | — | US | disclosed |
| US-7151107-B2 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2006-12-19 | — | — | US | disclosed |
| EP-1453511-B1 | TROPANE DERIVATIVES HAVING DOPAMINE REUPTAKE INHIBITOR ACTIVITY FOR THE TREATMENT OF ISCHEMIC DISEASES | NEUROSEARCH AS (DK) | 2006-11-15 | — | — | EP | disclosed |
| US-20050222187-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2005-10-06 | — | — | US | disclosed |
| US-6936621-B2 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2005-08-30 | — | — | US | disclosed |
| US-20050020621-A1 | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases | SANIONA A/S (DK) | 2005-01-27 | — | — | US | disclosed |
| US-20040122032-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2004-06-24 | — | — | US | disclosed |
| US-5981754-A | TREATMENT OF ANOXIA, ALZHEIMER'S DISEASE, SENILE DEMENTIA, SUBCORTICAL DEMENTIA SUCH AS HUNTINGTON'S CHOREA AND PARKINSON'S DISEASE, DEMENTIA CAUSED BY AIDS, NEUROPATHY | SANOFI (FR) | 1999-11-09 | — | — | US | disclosed |
| EP-0458696-B1 | Use of 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of medicaments for the treatment of cerebral and neuronal diseases | SANOFI SA (FR) | 1996-01-03 | — | — | EP | disclosed |
| US-5468753-A | Use of xaliproden or salt thereof to treat neurodegenerative disorders | SANOFI (FR) | 1995-11-21 | — | — | US | disclosed |
| US-5468753-A | Use of xaliproden or salt thereof to treat neurodegenerative disorders | SANOFI (FR) | 1995-11-21 | — | — | US | disclosed |
| US-5378709-A | ADMINISTERING 1-(2-NAPHTHYLETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TO MAMMALS | SANOFI (FR) | 1995-01-03 | — | — | US | disclosed |
| US-5270320-A | Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases | ELF SANOFI (FR) | 1993-12-14 | — | — | US | disclosed |
| US-5270320-A | Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases | ELF SANOFI (FR) | 1993-12-14 | — | — | US | disclosed |
| US-5229389-A | Inducing neuronal lesions in experimental animals by injecting vincristine | SANOFI (FR) | 1993-07-20 | — | — | US | disclosed |
| EP-0458696-A3 | USE OF 1-(2-NAPHTHYLETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF CEREBRAL AND NEURONAL DISEASES | — | 1992-03-18 | — | — | EP | disclosed |
| EP-0458696-A2 | Use of 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of medicaments for the treatment of cerebral and neuronal diseases | SANOFI (FR) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020621-A1 | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases | SLC6A2, SLC6A3, SLC18A2 | HTR2C 40/4885CCR2 2528/4885SOS1 3001/4885 |
| US-20040122032-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | KCNH1, KCNJ2, CACNA1B | HTR2C 334/4885CCR2 2483/4885SOS1 4670/4885 |
| US-20070054931-A1 | PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF | BDNF, KCNH1, GABRA6 | HTR2C 383/4885CCR2 2603/4885SOS1 4767/4885 |
| US-20050222187-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | KCNH1, ATP6V1B2, KCNJ6 | HTR2C 289/4885CCR2 2524/4885SOS1 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.